SELLAS Life Sciences Group, Inc.
SLS
$1.56
-$0.05-3.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.86M | 3.58M | 2.97M | 2.44M | 4.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.06M | 8.02M | 7.33M | 7.62M | 9.65M |
| Operating Income | -6.06M | -8.02M | -7.33M | -7.62M | -9.65M |
| Income Before Tax | -5.81M | -6.74M | -7.11M | -7.47M | -9.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.81M | -6.74M | -7.11M | -7.47M | -9.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.81M | -6.74M | -7.11M | -7.47M | -9.57M |
| EBIT | -6.06M | -8.02M | -7.33M | -7.62M | -9.65M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.07 | -0.09 | -0.10 | -0.13 | -0.21 |
| Normalized Basic EPS | -0.04 | -0.07 | -0.07 | -0.08 | -0.13 |
| EPS Diluted | -0.07 | -0.09 | -0.10 | -0.13 | -0.21 |
| Normalized Diluted EPS | -0.04 | -0.07 | -0.07 | -0.08 | -0.13 |
| Average Basic Shares Outstanding | 87.76M | 73.99M | 68.25M | 57.63M | 44.81M |
| Average Diluted Shares Outstanding | 87.76M | 73.99M | 68.25M | 57.63M | 44.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |